Imciromab pentetate

N/A

Report date: 2025/09/08 11:00:33

Base Information

Drug NameImciromab pentetate
Drug Alias NameMifarmonab英西单抗喷替酸英西单抗Imciromabum戊酸印西洛马 +[16] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Fab fragmentBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody murineRadiation-emitting products > Radioactive diagnostic agent +[5] 
Mechanisms of ActionCardiac myosin modulators
TargetsCardiac myosin
Therapy Area/IndicationsContrast agentsDiagnostic agents
Global Approved IndicationsContrast agentsDiagnostic agents
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date1996/07/03
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusWithdrawn
Highest Status in ChinaN/A
Originator CompaniesJohnson & Johnson Innovative Medicine
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesJanssen Biotech Inc
Active IndicationsN/A
Inactive IndicationsContrast agentsDiagnostic agents

Other Information

ATC CodeL01XC
Related LinksWikipediaDrugBankKEGG